Small-cap stocks hovered above the broader market Wednesday for most of the day as upbeat news surfaced from a variety of sectors.

Cypress Bioscience ( CYPB) was still riding high after surging late Tuesday on positive preliminary results from a late-stage trial of milnacipran for treatment of fibromyalgia syndrome. Shares nearly doubled at $16.37 after a CIBC World Markets analyst upped the stock to outperform. Forest Laboratories ( FRX), which jointly announced these results with Cypress, lately added 2.2% to $53.

Semiconductor Advanced Analogic Technologies ( AATI) also garnered an upgrade -- to buy from hold, at Needham & Co. -- after Tuesday's after-hours announcement of a favorable "initial determination" ruling from a patent-infringement case brought by Linear Technology ( LLTC). After an extended-trading leap, AnalogicTech shares still climbed 16.5% higher to $9.33. Linear slid 3.6% to $35.79.

Cypress and Analogic both supported the Russell 2000, which enjoyed a few hours on the upswing before careening down to flat-line along with the rest of the market. The index was off 0.4% at 836.54.

Also among small-cap gainers today was Mesa Laboratories ( MLAB). Shares vaulted 22.6% to $22.68 after the Colorado-based medical-equipment maker reported fiscal fourth-quarter earnings of $1.4 million, or 44 cents a share, compared with 27 cents a share a year ago. Sales soared 53.6% to $5.3 million.

SenoRx ( SENO), based in California, said the Food and Drug Administration cleared for commercialization its Multi-Lumen Radiation Balloon Applicator for brachytherapy in breast cancer patients. (Brachytherapy involves implanting small radioactive "seeds" that kill cancer cells.) Shares jumped 13.5%, or $1.08, to $9.08.

American Technology ( ATCO), meanwhile, traded some 23% higher to $3.98 after saying the U.S. Navy and Army chose the San Diego-based company's LRAD 500 acoustic hailing and warning device for small vessels and vehicles.

Children's footwear maker Stride Rite ( SRR), which agreed to an $800 million takeout by Payless ShoeSource ( PSS), surged 30.9% to $20.21 and provided strong support to the S&P SmallCap 600, but the index still weighed under the broader market's afternoon slide. The index slipped 2.09 points to 434.22.

Among those pulling down the tracker was Minneapolis medical-device maker Possis Medical ( POSS), which plunged 9.8% to $12.09 after breaking even for the quarter ended April 30 to fall a nickel short of Thomson Financial's per-share earnings consensus for the quarter ended April 30.

Likewise for fellow components Pep Boys ( PBY), an auto-parts retailer, and Maximus ( MMS), a business-services firm. Pep Boys slid 5.6% to $18.82 after coming in below sales estimates for the quarter ended May 5, and Maximus was cut to hold from buy at Stifel Nicolaus, pressuring shares down 4.2% to $41.65.

Elsewhere in negative territory, Vion Pharmaceuticals ( VION) took a 57.4% nosedive to 86 cents after the New Haven, Conn., biotech halted a late-phase study of leukemia drug Cloretazine "pending a detailed review of all of the data from the trial."

TRM ( TRMM), an Oregon-based purveyor of ATM and photocopy services, tumbled 25.5% to $1.81 after announcing dwindling fourth-quarter revenue and a widening loss vs. last year, as well as the resignation of Chief Executive Jeffrey Brotman, who will stay on as a non-executive chairman. His CEO role will be assumed by the current chief operating officer, Richard Stern, as of June 15.

If you liked this article you might like

Lackluster Finish for U.S. Stocks

Lackluster Finish for U.S. Stocks

Stocks Continue to Waver at the Flat Line

Stocks Continue to Waver at the Flat Line

Oil Slides as Stocks Post a Mixed Showing

Oil Slides as Stocks Post a Mixed Showing

Stocks Flutter Near the Flat Line

Stocks Flutter Near the Flat Line

Wall Street Falls Amid Inflation Talk

Wall Street Falls Amid Inflation Talk